CJC-1295 Key Points
- Very Long Acting
- Moderate Effect on GH
- Influences Basal Secretion
- No effect on Peak Amplitude, Frequency
- High Specificity for GH
CJC-1295 was first described in 2005 by Jette et al. The drug was under the development of ConjuChem in Montreal, Canada, which appeared focused on introducing it as a pharmaceutical product. During the mid 2000s, a series of Phase l/ll clinical trials were announced on CJC-1295. The drug was being investigated for the treatment of growth hormone deficiency, as well as the treatment of lipodystrophy associated with HIV infection. However, ConjuChem abruptly discontinued their lipodystrophy study in 2006 after the death of one participant. It is unclear if there was any relationship to the drug. One unconfirmed report has the subject dying shortly after receiving their 11th injection. Further research on CJC-1295 seems to have stalled at this point. The future of this agent as a pharmaceutical product remains unclear.
CJC-1295 is on the World Anti-Doping Agency's (WADA) list of prohibited substances. Methods for detecting the misuse of this compound are available.
Structural Characteristics of CJC-1295
CJC-1295 is a tetrasubstituted derivative of GRF 1-29 (sermorelin). It differs by the substitution of four amino acids, as well as the addition of a reactive maleimidoproprionic acid group. This group covalently binds the protein to serum albumin, greatly extending its half-life in the body. The specific structure of CJC-1295 is Tyr-D-Ala-Asp-Ala-lle-Phe-Thr-GIn-Ser-Tyr-Arg-Lys-Val-Leu-Ala-GIn-Leu-Ser-Ala-Arg-Lys-Leu-Leu-GIn-Asp-lle-Leu-Ser-Arg-Lys(Maleimidopropionyl)-NH2
CJC-1295 is an unapproved new drug. A thorough understanding of its safety and propensity for side effects in humans is lacking at this time.
This drug should never be used during pregnancy, with cancer, a history of cancer, diabetic retinopathy, sclerosing diseases of the liver or lungs, intracranial hypertension, or uncontrolled diabetes.
How is CJC-1295 Supplied
CJ-1295 is not available as a pharmaceutical product. No standard dosage information is available.
This drug can be purchased as a research compound or gray market supplement only. It is typically supplied in multi-dose vials containing 2mg or 5mg of dry lyophilized powder. This must be reconstituted with saline or bacteriostatic water before use. All unused portions of this drug should be kept under refrigeration.
CJC-1295 Side Effects (General)
Common side effects to CJC-1295 include flushing, warmth, dizziness, and transient hypotension following injection. Other common side effects include headache, diarrhea, nausea, and abdominal pain. Many side effects are dose dependent. In studies this drug appeared to be especially well tolerated at doses of 30 and 60 mcg/kg, while more significant side effects were noted with 125 and 250 mcg/kg doses. Also frequently reported are adverse effects typically associated with other types of growth hormone therapy, such as water retention (edema), joint pain (arthralgias), carpal tunnel syndrome, and numbness or tingling in the extremities. Note that the incidence of GFI-related side effects tends to be lower with GHRP therapy as compared to traditional hGFl.This is because GH/IGF-1 release is subject to the limits of endogenous synthesis, and as such the drug is less amenable to overdosing.
CJC-1295 Side Effects (Injection site)
The subcutaneous administration of this drug may cause redness, itching, pain, or lumps at the site of injection. Injection site reactions occurred in approximately 70% of subjects receiving CJC-1295 by subcutaneous injection in one study.
CJC-1295 Side Effects (Impaired glucose tolerance)
This drug may impair glucose tolerance and raise blood sugar levels,. This may occur in individuals without preexisting diabetes or impaired glucose tolerance.
CJC-1295 may be given by subcutaneous or intramuscular injection, or IV infusion. The subcutaneous route is most often applied.
This drug has not been approved for use in humans. Prescribing guidelines are unavailable.
When used for physique- or performance-enhancing purposes, CJC-1295 is generally administered at a dosage of 1000-2000 meg (1-2 mg). This is given 1-2 times per week. Cycles usually last 3-4 months, though programs of 6 months or longer are not uncommon. During investigatory studies with this drug, significant antibody formation (which might reduce the effectiveness of CJC-1295) was not reported. This suggests that desensitization is not likely to be rapid, if it does occur.
During clinical studies, CJC-1295 seemed to exert its optimal effect (tolerance, benefits) at a dosage of 30-60 mcg/kg. This was administered once every 7 or 14 days. The calculated amount would be roughly 2.5 to 5 mg for someone weighing 85 kg, which is similar to the common cumulative dosage range of CJC-1295 in the fitness community. Higher doses (up to 250 mcg/kg or 20 mg total for someone weighing 85 kg) were also well tolerated in studies, but with a higher incidence of side effects.
CJC-1295 Combination Therapy
CJC-1295 (a GHRH) may be combined with a drug from the GHRP (Growth Hormone Releasing Peptides) class, such as such as GHRP-2, GHRP-6, hexarelin, ipamorelin, or MK-677. These two drug types alter GH release through distinct and complimentary mechanisms. Such combination therapy tends to produce substantial synergy with regard to GH release.
CJC-1295 is not available as a prescription drug product. It is sold exclusively as a "research compound" or gray market supplement. Note that the quality of gray market products can be difficult to assure.
Wlliam Llewellyn (2011) - Anabolics